Rapidly progressive glomerulonephritis medical therapy

Jump to navigation Jump to search

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis medical therapy

CDC on Rapidly progressive glomerulonephritis medical therapy

Rapidly progressive glomerulonephritis medical therapy in the news

Blogs on Rapidly progressive glomerulonephritis medical therapy

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Accociate editor-in-Chief: Nazia Fuad M.D.

Overview

Treatment for rapidly progressive glomerulonephritis include supportive treatment and specific treatment. Supportive treatment is to treat the infection if there is one, correct the volume status with dialysis if required and smoking cessation. Specific therapy focuses on induction and maintenance of remission. Medical therapy focuses on to induce and then maintain the remission. Two pharmacologic agents used for induction of remission in patients with rapidly progressive glomerulonephritis are glucocorticoids (high dose) and cyclophosphamide. Cyclophosphamide is necessary to prevent relapse. Azathioprine or methotrexate is used for maintenance therapy. Azathioprine (AZA) is recommended after a 3-month induction period of cyclophosphamide.

.

Medical therapy

Medical therapy focuses on to induce and then maintain the remission.

Pharmacologic Therapy

Induction of remission

Two pharmacologic agents that are used for induction of remission in patients with rapidly progressive glomerulonephritis are;

  • Glucocorticoids (high dose)
  • Cyclophosphamide
Glucocorticoids[1]

Preffered regimen (1) : Methylprednisone, 7 mg/kg/d, Intravenous at a maximum dose of 1 g for 3 days

preffered regimen (2) :Prednisone, 1 mg/kg/d ,PO at a maximum dose of 80 mg for 3 weeks.

Then 2 mg/kg/d, PO at a maximum dose of 120 mg for 3 months.

Then taper patient off steroids by deceasing 25% of prednisone dose every 4 weeks until patient stops

Immunosuppressive Therapy
  • Preffered regimen(1) : Cyclophosphamide:IV: 15 mg/kg (maximum dose: 1,200 mg) every 2 weeks for 3 doses,
    • followed by maintenance pulses of 15 mg/kg IV (maximum dose: 1,200 mg) every 3 weeks until after remission is achieved[2]
  • Preffered regimen(2) :Cyclophosphamide PO:1.5- 2 mg/kg/day until remission is achieved, followed by 1.5 mg/kg/day for 3 more months.
  • Preffered regimen(3) :Rituximab IV, 375 mg/m2 once weekly, 4 dose

Maintenance of Remission

  • Preffered regimen (1) , Azathioprine, PO, 2 mg/kg for 6-12 months
  • Preffered regimen (2) :Methotrexate, PO,20mg per week for 12 months.

Other
Some medications have never been studied. However, they have been shown to be effective based on findings in case reports. These medications include:

  • IV immunoglobulins (Igs)
  • Antithymocyte antibody
  • Monoclonal antibodies to CD4
  • Monoclonal antibodies to CD25

Plasma Exchange

Indications of plasma exchange:

  • Removal of circulating auto-antibodies in patients with anti-GBM antibody disease
  • Patients with high risk of renal failure
  • Patients with serum creatinine > 2.3 mg/dL[3]
  • Patients who do not respond to pharmacologic therapy
  • Patients diagnosed with pauci-immune crescenteric glomerulonephriits with end stage renal disease and need dialysis[3]

References

  1. Nachman PH, Hogan SL, Jennette JC, Falk RJ (1996). "Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis". J Am Soc Nephrol. 7 (1): 33–9. PMID 8808107.
  2. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO (May 2009). "Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial". Ann. Intern. Med. 150 (10): 670–80. PMID 19451574.
  3. 3.0 3.1 Levy JB, Pusey CD (1997). "Still a role for plasma exchange in rapidly progressive glomerulonephritis?". J Nephrol. 10 (1): 7–13. PMID 9241619.

Template:WH Template:WS